Stifel Nicolaus Affirms Buy Rating on Vitamin Shoppe (VSI) Amid Sell-Off

Following a 9 percent decline in shares Wednesday, Stifel Nicolaus' David Schick just issued a research note defending Vitamin Shoppe (NYSE: VSI).

The stock is getting clobbered amid recent studies which show the use of vitamins may actually be detrimental to health. Shares of GNC Holdings (NYSE: GNC), Schiff Nutrition (NYSE: WNI) and Reliv (Nasdaq: RELV) are also pushing lower this afternoon.

Schick argues the linkage news will not impact long-term demand for vitamins and supplements, but does warn of a near-term impact on buying and traffic.

The analyst maintains a Buy rating and $52 price target on shares of Vitamin Shoppe.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Idex Corp. (IEX) Reiterated at Buy by Stifel
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand